In summary, we have shown that an intercomplementing toxin specifically targeting ERK/MAPK-dependent cells with high cell surface uPA and MMP activity holds promise as a novel candidate drug for the treatment of HNSCC. This evidence concerns the gene PLAU and head and neck squamous cell carcinoma.